Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin

International Journal of Cancer

Volumn 77, Issue 5, 1998, Pages 741-746

  Fink, Daniel ^a,e   Nebel, Sibylle ^a   Norris, Paula S ^a   Baergen, Rebecca N ^a   Wilczynski, Sharon P ^b   Costa, Michael J ^c   Haas, Martin ^a   Cannistra, Stephen A ^d   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b City of Hope ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASE MISPAIRING; CHO CELL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHO CELLS; CISPLATIN; CLONE CELLS; CRICETINAE; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENETIC ENGINEERING; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, NUDE; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031855988     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO;2-4     Document Type: Article

References (23)

1. AEBI, S., KURDI-HAIDAR, B., GORDON, R., CENNI, B., ZHENG, H., FINK, D., CHRISTEN, R.D., BOLAND, C.R., KOI, M., FISHEL, R. and HOWELL, S.B., Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56, 3087-3090 (1996).
2. ANTHONEY, D.A., MCILWRATH, A.J., GALLAGHER, W.M., EDLIN, A.R.M. and BROWN, R., Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res., 56, 1374-1381 (1996).
3. BHATTACHARYYA, N.P., SKANDALIS, A., GANESH, A., GRODEN, J. and MEUTH, M., Mutator phenotypes in human colorectal carcinoma cell lines. Proc. nat. Acad. Sci. (Wash.), 91, 6319-6323 (1994).
4. BOYER, J.C., UMAR, A., RISINGER, J.I., LIPFORD, J.R., KANE, M., YIN, S., BARRETT, J.C., KOLODNER, R.D. and KUNKEL, T.A., Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res., 55, 6063-6070 (1995).
5. BRANCH, P., AQUILINA, G., BIGNAMI, M. and KARRAN, P., Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature (Lond.), 362, 652-654 (1993).
6. BROWN, R., HIRST, G.L., GALLAGHER, W.M., MCILWRATH, A.J., MARGISON, G.P., VAN DER ZEE, A.G.J. and ANTHONEY, D.A., hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 15, 45-52 (1997).
7. DE LAS ALAS, M., AEBI, S., FINK, D., HOWELL, S.B. and LOS, G., Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J. not. Cancer Inst., 89, 1537-1541 (1997).
8. FINK, D., AEBI, S. and HOWELL, S.B., The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 4, 1-6 (1998a).
9. FINK, D., NEBEL, S., AEBI, S., ZHENG, H., CENNI, B., NEHME, A., CHRISTEN, R.D. and HOWELL, S.B., The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56, 4881-4886 (1996).
10. FINK, D., NEBEL, S., NORRIS, P.S., AEBI, S., KIM, H.K., HAAS, M. and HOWELL, S.B., The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Brit. J. Cancer, 77, 703-708 (1998b).
11. FINK, D., ZHENG, H., NEBEL, S., NORRIS, P.S., AEBI, S., LIN, T-P., NEHME, A., CHRISTEN, R.D., HAAS, M., MACLEOD, C.L. and HOWELL. S.B., In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res., 57, 1841-1845 (1997).
12. FISHEL, R. and KOLODNER, R.D., Identification of mismatch repair genes and their role in the development of cancer. Curr. Opin. Genet. Develop., 5, 382-395 (1995).
13. FUJITA, M., ENOMOTO, T., YOSHINO, K., NOMURA, T., BUZARD, G.S., INOUE, M. and OKUDAIRA, Y., Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int. J. Cancer, 64, 361-366 (1995).
14. HAWLEY, R.G., FONG, A.Z.C., BURNS, B.F. and HAWLEY, T.S., Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J. exp. Med., 176, 1149-1163 (1992).
15. IONOV, Y., PEINADO, M.A., MALKHOSYAN, S., SHIBATA, D. and PERUCHO, M., Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (Lond.), 363, 558-561 (1993).
16. KING, B.L., CARCANGIU, M-L., CARTER, D., KIECHLE, M., PFISTERER, J., PFLEIDERER, A. and KACINSKI, B.M., Microsatellite instability in ovarian neoplasms. Brit. J. Cancer, 72, 376-382 (1995).
17. KINZLER, K.W. and VOGELSTEIN, B., Lessons from hereditary colorectal cancer. Cell, 87, 159-170, 1996.
18. KOI, M., UMAR, A., CHAUHAN, D.P., CHERIAN, S.P., CARETHERS, J.M., KUNKEL, T.A. and BOLAND, C.R., Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res., 54, 4308-4312 (1994).
19. MILLER, D.G. and MILLER, A.D., Tunicamycin treatment of CHO cells abrogates multiple blocks to retrovirus infection, one of which is due to a secreted inhibitor. J. Virol., 66, 78-84 (1992).
20. NAVIAUX, R.K., COSTANZI, E., HAAS, M. and VERMA, I.M., The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol., 70, 5701-5705 (1996).
21. RICHARDS, B., ZHANG, H., PHEAR, G. and MEUTH, M., Conditional mutator phenotypes in hMSH2-deficient tumor cell lines. Science, 277, 1523-1526 (1997).
22. SKIPPER, H.E., SCHABEL, F.M. and LLOYD, H.H., Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells. Semin. Hematol., 15, 207-219 (1978).
23. UMAR, A., KOI, M., RISINGER, J.I., GLAAB, W.E., TINDALL, K.R., KOLODNER, R.D., BOLAND, C.R., BARRETT, J.C. and KUNKEL, T.A., Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res., 57, 3949-3955 (1997).